EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer

Tetsuyo Maeda, Makiko Ono, Tomo Osako, Tomohiro Chiba, Satoko Baba, Asumi Iesato, Yukinori Ozaki, Yuka Inoue, Natsue Uehiro, Yoko Takahashi, Takayuki Kobayashi, Takahiro Kogawa und 4 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tetsuyo Maeda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Membrane Proteins, Biomarkers, Tumor. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with triple negative breast cancer (TNBC) who have a poor response to neoadjuvant chemotherapy (NAC) have worse survival and new treatment strategies need to be developed. TNBC is considered a subtype in which the cyclic GMP‐AMP synthase (cGAS) is linked to the stimulator of interferon genes (STING) pathway, an innate immune response that recognizes cytosolic nucleic acid components, is activated when DNA damage occurs, and is attracting attention as a new therapeutic target.

Methods

Patients with TNBC who underwent surgery following NAC and for whom pre‐ and post‐treatment tissue specimens were available were enrolled in this study. To examine the association of STING expression with immune profiles and prognosis, STING, cGAS, CD8, and programmed cell death ligand 1 (PD‐L1) expressions in tumor cells (TCs) and immune cells (ICs), and tumor infiltrating lymphocytes (TILs) were assessed using immunohistochemistry of specimens obtained at pre‐treatment and at surgery.

Results

Ninety‐one cases were eligible, of which 68 cases were evaluable and included in the analysis. The high STING expression at baseline was marginally correlated with TILs, but not with CD8 + cells or PD‐L1 expression. Patients with sustained high expression of STING before and after NAC had a significantly poorer prognosis than that of others for distant recurrence‐free survival and breast cancer‐specific survival independent of nodal status, lymphatic invasion and therapeutic effects ( p = 0.024 and 0.014, respectively).

Conclusion

TNBCs with sustained high STING expression following NAC demonstrated a poor prognosis and will be a target for new treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsMembrane ProteinsBiomarkers, TumorHumansFemalePrognosisMiddle AgedLymphocytes, Tumor-InfiltratingAdultAgedNeoadjuvant TherapyB7-H1 AntigenNucleotidyltransferasesSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Stichwörter der Autor:innen

NACSTINGTNBCchanges in STING expressionprognosis

Substanzen

Membrane ProteinsB7-H1 AntigenBiomarkers, TumorNucleotidyltransferasesSTING1 protein, humanSTING ProteinCD274 protein, humancGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Autor:innen und Institutionen

  • Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Advanced Medical Development, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Breast and Endocrine Surgery, St Marianna University School of Medicine, Kawasaki, Japan.

ORCID-Profile: Takayuki Ueno

Zitieren

APA

Maeda, T., Ono, M., Osako, T., Chiba, T., Baba, S., Iesato, A., Ozaki, Y., Inoue, Y., Uehiro, N., Takahashi, Y., Kobayashi, T., Kogawa, T., Ohta, T., Kitano, S., Ueno, T., & Ohno, S. (2025). Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70666

Vancouver

Maeda T, Ono M, Osako T, Chiba T, Baba S, Iesato A, et al. Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70666

BibTeX
@article{Maeda2025,
  author = {Maeda, Tetsuyo and Ono, Makiko and Osako, Tomo and Chiba, Tomohiro and Baba, Satoko and Iesato, Asumi and Ozaki, Yukinori and Inoue, Yuka and Uehiro, Natsue and Takahashi, Yoko and Kobayashi, Takayuki and Kogawa, Takahiro and Ohta, Tomohiko and Kitano, Shigehisa and Ueno, Takayuki and Ohno, Shinji},
  title = {Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70666}
}
Kostenlos starten →